South Africa is likely to withdraw approval of nevirapine in the prevention of mother-to-child transmission (MTCT) of HIV infections unless Boehringer Ingelheim produces new data to support the use of the drug in this indication

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.425, 2003-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Controversies in the use of nevirapine for prevention of mother-to-child transmission of HIV

By McIntyre James A  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 6, 2006-04 ,pp. : 677-685

Informa Healthcare

Access to resources Recommend Favorite

New hope in the prevention of mother-to-child transmission of HIV

By  

Inpharma, Vol. 1, Iss. 1249, 2000-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Antiretroviral Therapy for Prevention of Mother-to-Child HIV Transmission: Focus on Single-Dose Nevirapine

By Giaquinto Carlo  

Clinical Drug Investigation, Vol. 26, Iss. 11, 2006-01 ,pp. : 611-627

Adis International

Access to resources Recommend Favorite

Nevirapine regimens best value for mother-to-child HIV prevention

By  

Inpharma, Vol. 1, Iss. 1532, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Nevirapine regimens best value for mother-to-child HIV prevention

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 500, 2006-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite